• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Moderna Stock Is Up 5.3% What's Changed After Profit Return

    Simply Wall St·11/09/2026 02:24:11
    Listen to the news
    • Moderna reported third quarter 2026 revenue of US$1.313b and net income of US$162m, raised its full year revenue outlook, trimmed its 2026 R&D budget by US$200m, and recorded approvals and positive late stage data across its respiratory and oncology franchises.
    • Alongside higher demand for its mNEXSPIKE COVID vaccine, Moderna is starting to show tangible diversification. The company has received Health Canada approvals for mFLUSIVA and the mCOFLU combo shot, and reported Phase 3 melanoma data for intismeran autogene that support the push into individualized cancer treatments.
    • We will now look at how Moderna's investment narrative could be reshaped by its return to quarterly profit and raised revenue guidance.

    Scan beyond Moderna and evaluate other vaccine and healthcare names that could be positioned for similar momentum with our curated list of 35 healthcare AI stocks.

    What Is Moderna's Investment Narrative?

    To own Moderna, you need to believe this is evolving from a single product story into a broader mRNA platform that can support multiple commercial franchises. The Q3 profit and raised full year revenue outlook speak to demand and pricing power in COVID for now, while approvals for mFLUSIVA and mCOFLU, plus the intismeran melanoma data with Merck, point to more diversified drivers. Trimming the 2026 R&D budget by US$200m shows some discipline around cash burn, although this is still a capital hungry research business rather than a mature cash cow.

    In the short term, execution on respiratory vaccine launches and the regulatory path for intismeran look like the key operational catalysts. The recent run in the share price and a P/S of 40.7x against lower peer multiples suggests expectations are already demanding, especially with the group still reporting a net loss of US$1,963m over the first nine months of 2026. Volatile trading over the past quarter underlines how quickly sentiment around this pipeline driven story can swing when trial results or guidance shift.

    Even so, there is a less visible pressure point in Moderna's set up that only becomes clear once you look closely at...

    There's only one way to know the right time to buy, sell or hold Moderna. Head to Simply Wall St's company report for the latest analysis of Moderna's Fair Value.

    NasdaqGS:MRNA 1-Year Stock Price Chart
    NasdaqGS:MRNA 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate take focuses on Moderna’s personalized oncology plans as the weak link. The most cautious analysts were modeling revenue of about US$2.6b and earnings of roughly US$451.8m by 2029, and still arrived at a much lower price target. That gap shows how sharply opinions can differ, so it is useful to compare several viewpoints yourself.

    Explore 5 other Moderna fair value estimates, including one that suggests as much as 63% downside from the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Moderna?

    If Moderna has you thinking more broadly about where to put fresh capital to work, it can help to compare it with other opportunities that have different risk and income profiles. The Simply Wall St Screener gives you a quick way to scan across sectors and filter for the traits that matter most to you.

    • If capital preservation is top of mind, focus on businesses that historically show fewer earnings and price shocks by reviewing 31 resilient stocks with low risk scores that score well on resilience.
    • If you care most about quality at a sensible entry point, compare Moderna with a curated pool of companies that combine cleaner balance sheets and stronger fundamentals through the list of solid balance sheet and fundamentals (25 results).
    • If you are hunting for opportunities that sit off the beaten track but still have solid underlying metrics, widen your search to a 19 high quality undiscovered gems that might deserve a spot on your watchlist.